Document Type

Conference Proceeding

Abstract

  • Liposomal bupivacaine is an extended-release formulation of the long-acting traditional local anesthetic, bupivacaine.
  • Yale New Haven Health system (YNHHS) removed liposomal bupivacaine from formulary in March 2024.
  • This decision was based on primary research and meta-analyses showing little to no clinical or statistical benefit of liposomal bupivacaine over traditional bupivacaine in morphine milligram equivalent use (MME) and median pain score in all surgeries including lobectomies.

Publication Date

12-2024

Comments

Presented at the 59th Annual ASHP Midyear Clinical Meeting; New Orleans, LA December 8-12, 2024. Disclosure: The authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Kelly Cheng: Nothing to disclose, Michael Guerra: Nothing to disclose, Rebecca Pulk: Nothing to disclose, Amber Zaniewski: Nothing to disclose, Ryan Brown: Nothing to disclose.

References

Thuppal S, Sleiman A, Chawla K, et al. Randomized Trial of Bupivacaine Versus Liposomal Bupivacaine in Minimally Invasive Lobectomy. Ann Thorac Surg. 2022;114(4):1128-1134. doi:10.1016/j.athoracsur.2022.02.058 2. Hussain N, Brull R, Sheehy B, et al. Perineural Liposomal Bupivacaine Is Not Superior to Nonliposomal Bupivacaine for Peripheral Nerve Block Analgesia. Anesthesiology. 2021;134(2):147-164. doi:10.1097/ALN.0000000000003651 3. Weksler B, Sullivan JL, Schumacher LY. Randomized trial of bupivacaine with epinephrine versus bupivacaine liposome suspension in patients undergoing minimally invasive lung resection. J Thorac Cardiovasc Surg. 2021;161(5):1652-1661. doi:10.1016/j.jtcvs.2020.01.112

Share

COinS